Literature DB >> 22143144

Breast cancer: Should we assess HER2 status by Oncotype DX?

Michail Ignatiadis, Christos Sotiriou.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22143144     DOI： 10.1038/nrclinonc.2011.188

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

Review 1.  Gene-expression signatures in breast cancer.

Authors:  Christos Sotiriou; Lajos Pusztai
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

2.  HER-2 as a target for breast cancer therapy.

Authors:  Michail Ignatiadis; Christine Desmedt; Christos Sotiriou; Evandro de Azambuja; Martine Piccart
Journal:  Clin Cancer Res       Date:  2009-03-15       Impact factor: 12.531

3.  Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).

Authors:  A Noske; S Loibl; S Darb-Esfahani; M Roller; R Kronenwett; B M Müller; J Steffen; C von Toerne; R Wirtz; I Baumann; G Hoffmann; G Heinrich; S T Grasshoff; H U Ulmer; C Denkert; G von Minckwitz
Journal:  Breast Cancer Res Treat       Date:  2010-12-29       Impact factor: 4.872

4.  Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Authors:  Soonmyung Paik; John Bryant; Elizabeth Tan-Chiu; Edward Romond; William Hiller; Kyeongmee Park; Ann Brown; Greg Yothers; Steve Anderson; Roy Smith; D Lawrence Wickerham; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2002-06-05       Impact factor: 13.506

5.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; Jared N Schwartz; Karen L Hagerty; D Craig Allred; Richard J Cote; Mitchell Dowsett; Patrick L Fitzgibbons; Wedad M Hanna; Amy Langer; Lisa M McShane; Soonmyung Paik; Mark D Pegram; Edith A Perez; Michael F Press; Anthony Rhodes; Catharine Sturgeon; Sheila E Taube; Raymond Tubbs; Gail H Vance; Marc van de Vijver; Thomas M Wheeler; Daniel F Hayes
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

6.  High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study.

Authors:  David J Dabbs; Molly E Klein; Syed K Mohsin; Raymond R Tubbs; Yongli Shuai; Rohit Bhargava
Journal:  J Clin Oncol       Date:  2011-10-11       Impact factor: 44.544

7.  Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

Authors:  Frederick L Baehner; Ninah Achacoso; Tara Maddala; Steve Shak; Charles P Quesenberry; Lynn C Goldstein; Allen M Gown; Laurel A Habel
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

Review 8.  Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.

Authors:  Guido Sauter; James Lee; John M S Bartlett; Dennis J Slamon; Michael F Press
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

9.  Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.

Authors:  J Lehmann-Che; F Amira-Bouhidel; E Turpin; M Antoine; H Soliman; L Legres; C Bocquet; R Bernoud; E Flandre; M Varna; A de Roquancourt; L-F Plassa; S Giacchetti; M Espié; C de Bazelaire; L Cahen-Doidy; E Bourstyn; A Janin; H de Thé; P Bertheau
Journal:  Br J Cancer       Date:  2011-05-03       Impact factor: 7.640
  9 in total
  6 in total

1.  Patient profiling in breast cancer--is knowledge power?

Authors:  Rebecca Kirk; M Teresa Villanueva; Lisa Hutchinson
Journal:  Nat Rev Clin Oncol       Date:  2011-12-21       Impact factor: 66.675

Review 2.  Perspectives on systems biology applications in diabetic kidney disease.

Authors:  Claudiu V Komorowsky; Frank C Brosius; Subramaniam Pennathur; Matthias Kretzler
Journal:  J Cardiovasc Transl Res       Date:  2012-06-26       Impact factor: 4.132

3.  Rapidly quantifying drug sensitivity of dispersed and clumped breast cancer cells by mass profiling.

Authors:  Jennifer Chun; Thomas A Zangle; Theodora Kolarova; Richard S Finn; Michael A Teitell; Jason Reed
Journal:  Analyst       Date:  2012-10-11       Impact factor: 4.616

4.  A novel quantitative immunohistochemistry method for precise protein measurements directly in formalin-fixed, paraffin-embedded specimens: analytical performance measuring HER2.

Authors:  Kristian Jensen; Rikke Krusenstjerna-Hafstrøm; Jesper Lohse; Kenneth H Petersen; Helene Derand
Journal:  Mod Pathol       Date:  2016-10-21       Impact factor: 7.842

5.  A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections.

Authors:  Hiroaki Nitta; Brian D Kelly; Mary Padilla; Nikolaus Wick; Patrick Brunhoeber; Isaac Bai; Shalini Singh; Jim Ranger-Moore; Chris Bieniarz; Hitoshi Tsuda; Thomas M Grogan
Journal:  Diagn Pathol       Date:  2012-05-30       Impact factor: 2.644

6.  Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas.

Authors:  Anne Vincent-Salomon; Vanessa Benhamo; Eléonore Gravier; Guillem Rigaill; Nadège Gruel; Stéphane Robin; Yann de Rycke; Odette Mariani; Gaëlle Pierron; David Gentien; Fabien Reyal; Paul Cottu; Alain Fourquet; Roman Rouzier; Xavier Sastre-Garau; Olivier Delattre
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.